Winston-Salem, N.C. - Separate studies involving atopic dermatitis drugs tacrolimus (Protopic) and pimecrolimus (Elidel) show the topical immunomodulators (TIMs) are safe and effective for off-label use on children under age 2.
Skin Swab Analysis Reveals Early Predictors of Atopic Dermatitis in Infants
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
Lisa Swanson, MD, FAAD: Clinical Pearls and Updates for Pediatric Dermatology
The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma
Lawrence Eichenfield, MD: Outlining Late-Breaking INTEGUMENT-PED Data for Roflumilast in Pediatric Patients
Evolution and Innovation in Treating Psoriasis in Pediatric Patients